Applied Drug Delivery Institute and AAPS Announce 3rd Annual Academic Competition
The Catalent Applied Drug Delivery Institute in collaboration with the American Association of Pharmaceutical Scientists (AAPS) have announced details of the “3rd Annual Global Academic Competition for Life Science Leaders of Tomorrow”. The programme, which aims to encourage students’ interest and increase their knowledge of applied drug delivery technologies, is now open for entries via www.drugdeliveryinstitute.com/global-academic-competition.
The competition welcomes entries from eligible global university students enrolled in graduate programmes focused on the pharmaceutical sciences, industrial pharmacy, drug delivery, drug development or related disciplines.
Participating students will compete for one of five prizes of $2000, a complimentary, 1-year AAPS membership, and the opportunity to have their submissions published by Catalent in the Institute and/or industry publications.
Entries should take the form of an original review article based on topics such as drug development, improving therapeutic profiles and bioavailability, pre-formulation, drug delivery innovation in inhalation, biologics, lipid-based systems, crossing the blood-brain barrier, or on the delivery of drugs in certain patient groups such as pediatrics. The deadline for entries is 28 March 2014.
“The Global Academic Competition supports the mission of The Catalent Applied Drug Delivery Institute to foster education, collaboration, and adoption of drug delivery technologies to develop better treatments for patients,” stated Terry Robinson, Executive Director of the Institute. “We are delighted that AAPS is co-sponsoring the competition this year, and with their reach to 2500 student and postdoctoral Fellow members, and almost 100 student chapters in 35 countries around the globe, we look forward to expanding the number of participating universities.”
”The AAPS Awards Program provides a wonderful opportunity for scientists and students to be recognized and honored for their valuable contributions to the pharmaceutical sciences,” said John Lisack, Jr., CAE, AAPS executive director. “We are thrilled to collaborate with the Catalent Drug Delivery Institute again this year to award future leaders in the industry.”
Participating universities in the US include, St. John’s, Rutgers, New Jersey Institute of Technology, and University of North Carolina at Chapel Hill. In Europe, participating universities include Saarland and Düsseldorf, Germany and Bath and Bristol in the U.K.
Details of the Global Academic Competition including entry forms and the official contest rules can be found at http://www.drugdeliveryinstitute.com/global-academic-competition/.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance